About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
By
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
FEATURING
Robert Peter Gale
By
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
FEATURING
Robert Peter Gale
371 views
February 21, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
16:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…
Feat.
H. Hashmi
07:11
GRACE
CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…
Feat.
A. Goodman,
A. Jeong,
S. Rajeeve
13:07
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
Feat.
J. Chavez
19:08
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…
Feat.
R. Banerjee
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
09:18
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…
Feat.
J. Westin
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
14:09
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…
Feat.
H. Hashmi
08:23
Total Health
R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment
Feat.
J. Chandler,
B. Randolph,
M. Onciu
49:01
Scripps MD Anderson Cancer Center
Current Summary of the Multiple Myeloma Treatment Landscape
Feat.
R. Lu
12:35
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…
Feat.
C. Cerchione
26:46
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…
08:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…
Feat.
R. Bansal
04:08
GRACE
CAR T-Cell Therapy Side Effects for Blood Cancers
Feat.
A. Goodman
62:02
UChicago Medicine
New Treatment Strategies in DLBCL
Feat.
L. Sehn
31:51
Indy Hematology Review
Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…
Feat.
K. Anderson
09:45
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …
Feat.
M. Kamdar
16:03
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: The New Algorithm for 2L LBCL
Feat.
J. Westin
15:26
Moffitt Cancer Center
R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?
Feat.
A. Lazaryan
